Rtw Investments 13F: Adds $4.9M to AQST Stake
RTW Investments boosted its position in Aquestive Therapeutics by 18.8%, now holding 7.43 million shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rtw Investments added 1,176,471 shares to its stake in Aquestive Therapeutics, Inc. ($AQST), an 18.82% increase, according to a 13F filing with the SEC dated May 15, 2026. It reported 7,426,471 shares worth $30.89 million at the end of the quarter.
Since the filing, $AQST is down 1.2% after 1 week, up 1.2% after 1 month and down 9.3% to date (from the $4.17 close on May 15, 2026).
AQST
Aquestive Therapeutics, Inc.
Key Points
- RTW Investments increased its stake in Aquestive Therapeutics by 18.8%, adding 1.18 million shares for a total of 7.43 million shares worth $30.97 million.
- Rtw Investments held 7,426,471 $AQST shares at quarter end, up 18.82% from the prior quarter.
- Aquestive Therapeutics, traded on NasdaqGM under ticker AQST, has a market cap of about $523.1 million and a 52-week trading range of $2.93 to $7.55.
- Insiders, including Gregory Brown and Marco Taglietti, bought 50,500 shares each on June 10, 2026, while analysts maintain a positive outlook with multiple 'buy' ratings.
Get $AQST trade alerts by text
We text you when insiders, Congress or big funds trade $AQST. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Aquestive Therapeutics, Inc. alert may contain errors. Disclosures
RTW Investments has increased its stake in Aquestive Therapeutics, Inc. (NasdaqGM: AQST), adding 1.18 million shares. This move, reflected in a recent Form 13F filing with the SEC, brings its total holdings to 7.43 million shares, representing an 18.8% increase. The value of this position is approximately $30.97 million as of the filing date.
What Changed in RTW Investments' Aquestive Therapeutics Position
RTW Investments boosted its holdings in Aquestive Therapeutics by 18.8%, adding 1.18 million shares to its portfolio. Previously holding 6.25 million shares, the fund now owns 7.43 million shares, valued at about $30.97 million. This adjustment is part of its strategy as reported for the quarter ending March 31, 2026.
Other Institutional Activity in Aquestive Therapeutics
Several other institutional investors have also adjusted their positions in Aquestive Therapeutics. Bratton Capital Management, L.P. maintained its position with 9.81 million shares valued at $40.72 million. BlackRock, Inc. slightly reduced its stake by 266,331 shares, now holding 7.51 million shares worth $31.16 million. Vanguard Capital Management LLC established a new position with 4.44 million shares valued at $18.44 million. Federated Hermes, Inc. increased its holdings by 907,517 shares, bringing its total to 2.94 million shares valued at $12.20 million. Meanwhile, Balyasny Asset Management L.P. significantly boosted its stake by 1.93 million shares, now holding 2.90 million shares worth $12.04 million.
Aquestive Therapeutics, Inc. Stock Up 2.5%
Shares of Aquestive Therapeutics (NasdaqGM: AQST) traded near $4.17 recently. The company has a market capitalization of approximately $523.1 million. Although it is not profitable, with no meaningful P/E ratio, its forward P/E is noted as -9.27. The stock has a 52-week low of $2.93 and a high of $7.55. Its 50-day moving average is $4.14, while the 200-day moving average stands at $4.88. The company maintains a current ratio of 4.1 and a quick ratio of 3.7, indicating solid liquidity.
Recent Earnings
In its most recent earnings report, Aquestive Therapeutics posted revenue of $50.27 million, reflecting a growth rate of 65.7%. However, the company recorded a net margin of -137.1%, with earnings per share (EPS) of -$0.61. Investors are looking ahead to the next earnings release scheduled for August 11, 2026.
Insider Buying and Selling at Aquestive Therapeutics, Inc.
On June 10, 2026, several insiders at Aquestive Therapeutics made notable transactions. Gregory Brown, Julie Krop, Marco Taglietti, and John Cochran each purchased 50,500 shares. Abigail Jenkins sold 50,500 shares on the same day. These transactions were not conducted under a Rule 10b5-1 plan.
Analysts Set New Price Targets
Analysts remain optimistic about Aquestive Therapeutics. On November 7, 2025, Piper Sandler maintained its 'buy' rating with a target price of $8. JMP Securities also kept its 'buy' rating with a target of $12 on October 9, 2025. Oppenheimer reiterated its 'buy' rating with an $8 target on September 8, 2025. The consensus target price among analysts is approximately $8.89, with 9 analysts providing opinions.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a pharmaceutical company based in Warren, New Jersey. It develops and markets innovative drug delivery solutions, focusing on oral film formulations for various treatments, including epilepsy and opioid dependence. The company is led by CEO Daniel Barber and employs 147 people. Its pipeline includes several products in different stages of clinical trials, leveraging its PharmFilm technology.
Bottom Line
RTW Investments' increased stake in Aquestive Therapeutics signals confidence in the company's potential. Investors closely monitor such filings to understand fund strategies, though these positions are historical snapshots and may not reflect current holdings. Aquestive's innovative approach in drug delivery and its current market position make it a point of interest for both institutional investors and analysts.
Related Filing Alerts
Source: Rtw Investments's 13F filing on $AQST (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Rtw Investments 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts